Claims

1. A therapeutic fusion protein for enhancing efferocytosis comprising an integrin binding domain, a phosphatidylserine (PS) binding domain and a solubilizing domain, wherein the solubilizing domain is inserted between the integrin binding domain and the PS binding domain; and wherein the integrin binding domain binds to an integrin wherein the integrin binding domain has an amino acid sequence of SEQ ID NO: 77, or at least 90% sequence identity thereto and the PS binding domain has an amino acid sequence of SEQ ID NO: 3, or at least 90% sequence identity thereto, or the PS binding domain has an amino acid sequence of SEQ ID NO: 76, or at least 90% sequence identity thereto,, and wherein the solubilizing domain is HSA and has an amino acid sequence of SEQ ID NO: 4, or at least 90% sequence identity thereto.

2. A therapeutic fusion protein for enhancing efferocytosis comprising, SEQ ID NO: 42, or at least 90% sequence identity thereto.

3. A therapeutic fusion protein for enhancing efferocytosis comprising SEQ ID NO: 44, or at least 90% sequence identity thereto.

4. A therapeutic fusion protein for enhancing efferocytosis comprising SEQ ID NO: 46, or at least 90% sequence identity thereto.

5. A therapeutic fusion protein for enhancing efferocytosis comprising SEQ ID NO: 48, or at least 90% sequence identity thereto.

6. A therapeutic fusion protein for enhancing efferocytosis comprising SEQ ID NO: 80, or at least 90% sequence identity thereto.

7. A therapeutic fusion protein for enhancing efferocytosis comprising SEQ ID NO: 82, or at least 90% sequence identity thereto.

8. An isolated nucleic acid encoding the amino acid sequence of any one of claims 2 to 7.

9. A cloning or expression vector comprising the nucleic acid according to claim 8.

10. A recombinant host cell suitable for the production of a therapeutic fusion protein, comprising one or more cloning or expression vectors according to claim 9 and optionally, secretion signals.

11. A pharmaceutical composition comprising the fusion protein of any one of claims 2 to 7 and a pharmaceutically acceptable carrier.

12. The fusion protein of any one of claims 2 to 7 for use in the treatment or prevention of an inflammatory disorder or inflammatory organ injury in an individual in need thereof, wherein the inflammatory disorder or inflammatory organ injury is acute kidney injury, acute respiratory distress syndrome, acute liver injury, sepsis, myocardial infarction, stroke, burns, traumatic injury and inflammatory and organ injuries resulting from ischemia/reperfusion.

13. Use of the fusion protein of any one of claims 2 to 7 in the manufacture of a medicament for the treatment or prevention of an inflammatory disorder or inflammatory organ injury in an individual in need thereof, wherein the inflammatory disorder or inflammatory organ injury is acute kidney injury, acute respiratory distress syndrome, acute liver injury, sepsis, myocardial infarction, stroke, burns, traumatic injury and inflammatory and organ injuries resulting from ischemia/reperfusion.

14. The use according to claim 13, wherein the fusion protein is to be administered in combination with another therapeutic agent, wherein the therapeutic agent is an immunosuppressive agent, an immunomodulating agent, an anti-inflammatory agent, an anti-oxidant, an anti-infective agent, a cytotoxic agent or an anti-cancer agent.